rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2005-1-1-43-48rpcardio-342Research ArticleREVIEWSОБЗОРЫACE INHIBITORS IN PATIENTS WITH ISCHEMIC HEART DISEASE WITHOUT HEART FAILURE: CLASS EFFECTS AND EFFICACY OF ITS REPRESENTATIVESИИНГИБИТОРЫ АПФ У БОЛЬНЫХ СТАБИЛЬНОЙ ИБС БЕЗ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ: ЭФФЕКТЫ КЛАССА И ЭФФЕКТИВНОСТЬ ЕГО ПРЕДСТАВИТЕЛЕЙКарповЮ. А.KarpovY. A.Российский Кардиологический Научно-Производственный Комплекс МЗ и СР РФ, МоскваРоссияRussian Cardiological Research and Production Complex, Ministry of Health and Social Development of Russia, MoscowRussian Federation200525122015114348Copyright © Karpov Y.A., 20152015Карпов Ю.А.Karpov Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/342

Results of large-scale studies (QUIET, HOPE, EUROPA, PEACE, CAMELOT), devoted to assessment of the role of ACE inhibitors in treatment of patients with stable form of ischemic heart disease without heart failure are analyzed. Different efficacy of the representatives of this class toward risks of coronary events development and cerebral-vascular complications is shown, as well as the overall mortality risk due to cardiovascular reasons. Favorable therapeutic effects of inhibiting RAS activity in patients without left ventricle dysfunction are demonstrated in studies EUROPA with perindopril 8 mg, and HOPE with ramipril 10 mg. That became the ground of inclusion of these drugs into recommendations for treatment of all patients with ischemic heart disease after myocardial infarction, in addition to antiplatelet, lipid reducing remedies and beta-blockers.

Проанализированы результаты крупномасштабных исследований (QUIET, HOPE, EUROPA, PEACE, CAMELOT) по оценке роли ингибиторов АПФ в лечении больных стабильной ИБС без сердечной недостаточности. Показана эффективность представителей данного класса по влиянию на риск развития коронарных событий, цереброваскулярных осложнений, суммарный риск смерти от сердечно-сосудистых причин. Благоприятные терапевтические последствия ингибирования активности РАС у больных без дисфункции левого желудочка продемонстрированы в исследовании EUROPA с периндоприлом 8 мг и исследовании HOPE с рамиприлом 10 мг, что послужило основанием для включения данных препаратов в рекомендации по лечению всех больных стабильной ИБС после инфаркта миокарда дополнительно к антитромбоцитарным, липидснижающим средствам и бета-блокаторам. 

ингибиторы АПФишемическая болезнь сердцасердечно-сосудистый рискACE inhibitorsischemic heart diseasecardiovascular riskReferences2002 Heart and Stroke Statistical Update. American Heart Association: 11—13 International Cardiovascular Disease Statistics. American Heart Association., 2002: 1-6.2002 Heart and Stroke Statistical Update. American Heart Association: 11—13 International Cardiovascular Disease Statistics. American Heart Association., 2002: 1-6.Guidelines for the diagnosis and treatment of chronic heart failure. Task Force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 2001; 22:1527-1560.Guidelines for the diagnosis and treatment of chronic heart failure. Task Force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 2001; 22:1527-1560.Всероссийское научное общество кардиологов (ВНОК). Национальные рекомендации по диагностике и лечению артериальной гипертонии. М., 2004.Всероссийское научное общество кардиологов (ВНОК). Национальные рекомендации по диагностике и лечению артериальной гипертонии. М., 2004.Беленков Ю.Н., Мареев В.Ю. Принципы рационального лечения сердечной недостаточности. Медиа Медика, М., 2000, 267 c.Беленков Ю.Н., Мареев В.Ю. Принципы рационального лечения сердечной недостаточности. Медиа Медика, М., 2000, 267 c.ACC/AHA 2002 Guideline Update for the management of patients with chronic stable angina-summary article. A Report of the ACC/AHA Task Force on Practice Guidelines. Circulation 2003; 107: 149-158.ACC/AHA 2002 Guideline Update for the management of patients with chronic stable angina-summary article. A Report of the ACC/AHA Task Force on Practice Guidelines. Circulation 2003; 107: 149-158.Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a system￾atic overview of data from individual patients. ACE-inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-1581.Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a system￾atic overview of data from individual patients. ACE-inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-1581.The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.Dzau V, Bernstein K, Celermaier D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (Suppl L): 1-20.Dzau V, Bernstein K, Celermaier D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (Suppl L): 1-20.Pitt B, O`Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved ventricular function. Am J Cardiol 2001; 87: 1058-1063.Pitt B, O`Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved ventricular function. Am J Cardiol 2001; 87: 1058-1063.The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-53.The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-53.PROGRESS Collaborative group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475- 484.PROGRESS Collaborative group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475- 484.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomased, double-blind, placebo-controlled, multicen￾tre trial (the EUROPA study). Lancet 2003; 362; 782-788.The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomased, double-blind, placebo-controlled, multicen￾tre trial (the EUROPA study). Lancet 2003; 362; 782-788.PEACE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068.PEACE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068.Nissen SE, Tuscu EM, Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2226.Nissen SE, Tuscu EM, Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2226.Yusuf S, Pogue J. ACE inhibition in stable coronary artery disease (Letter). N Engl J Med 2005; 352: 937- 938.Yusuf S, Pogue J. ACE inhibition in stable coronary artery disease (Letter). N Engl J Med 2005; 352: 937- 938.Ferrari R. EUROPA: perindopril’s action on markers of thrombosis, inflammation, and endothelial dysfunction in coronary artery disease. Oral presentation. ESC Congress 2004, Munich, August 30.Ferrari R. EUROPA: perindopril’s action on markers of thrombosis, inflammation, and endothelial dysfunction in coronary artery disease. Oral presentation. ESC Congress 2004, Munich, August 30.Комитет экспертов ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации. Кардиоваскулярная терапия и профилактика, 2004г., приложение.Комитет экспертов ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации. Кардиоваскулярная терапия и профилактика, 2004г., приложение.

The authors declare that there are no conflicts of interest present.